Site Centers Corp. (SITC)
NYSE NYSE Primary 
XFRA 
Candel Therapeutics to highlight immunotherapy advances at SITC 2025
Candel Therapeutics Inc (NASDAQ:CADL) will deliver three presentations at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). “Candel's presentations at SITC 2025 exemplify our innovative approach to the discovery and development of novel immunotherapies,” said CEO Paul Peter Tak.
Here's What Key Metrics Tell Us About SITE Centers Corp. (SITC) Q4 Earnings
The headline numbers for SITE Centers Corp. (SITC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SITE CENTERS CORP. (SITC) Misses Q4 FFO and Revenue Estimates
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share.
Compared to Estimates, SITE Centers Corp. (SITC) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for SITE Centers Corp. (SITC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
SITE CENTERS CORP. (SITC) Q3 FFO and Revenues Miss Estimates
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.81 per share, missing the Zacks Consensus Estimate of $0.87 per share.
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 8-10 in Houston, USA.
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually. Details of the presentation are as follows: Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC Abstract Number: 765 Presenter: Reid Bissonnette, Ph.D.
SITC Closes Curbline Spin-Off, Disposes Properties Worth $610.1M
SITE Centers announces completion of Curbline spinoff. It also provides an update on its transaction activity from Sept.
SITE Centers (SITC) Q2 OFFO Beat Estimates, Stock Rises
SITE Centers' (SITC) second-quarter results benefit from growth in base rent per square foot and same-store NOI.
SITE Centers Corp. (SITC) Q2 2024 Earnings Call Transcript
SITE Centers Corp. (NYSE:SITC ) Q2 2024 Earnings Conference Call July 30, 2024 8:00 AM ET Company Participants Stephanie Ruys de Perez – Vice President-Capital Markets David Lukes – Chief Executive Officer Conor Fennerty – Chief Financial Officer Conference Call Participants Dori Kesten – Wells Fargo Craig Mailman – Citi Todd Thomas – KeyBanc Capital Markets Samir Khanal – Evercore ISI Floris van Dijkum – Compass Point Ronald Kamdem – Morgan Stanley Linda Tsai – Jefferies Alexander Goldfarb – Piper Sandler Paulina Rojas – Green Street Ki Bin Kim – Truist Jianfeng Wang – JPMorgan Operator Good day and welcome to the SITE Centers' Second Quarter 2024 Operating Results Conference Call. All participants will be in listen-only mode.
SITE Centers Corp. (SITC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for SITE Centers Corp. (SITC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SITE CENTERS CORP. (SITC) Q2 FFO Beat Estimates
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.27 per share, beating the Zacks Consensus Estimate of $0.24 per share.
